The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout.
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Read Also
- Fisker's fire sale deal comes with a giant asterisk
- If You Invested $100 In This Stock 15 Years Ago, You Would Have $23,000 Today
- Here's How Much You Would Have Made Owning Blackstone Stock In The Last 10 Years
- Trump Vs. Biden: Former President Retakes Lead In 2024 Election Poll After Debate, More Voters See Incumbent As 'Too Old'
- Here's How Much You Would Have Made Owning Permian Resources Stock In The Last 5 Years
- Here's How Much $100 Invested In Amkor Tech 20 Years Ago Would Be Worth Today
- A Successful Partnership Hinges on Careful Planning and Execution. Here Are 7 Things You Need to Ensure Partnership Success.
- Nvidia's CEO Sold Stock for the First Time This Year and Netted the Most He Ever Has in a Single Month
- Biden Should Step Aside, Say Business Leaders Including Walmart Heir
- Wharton's Jeremy Siegel Implores Jerome Powell To Signal September Rate Cuts: 'We Are In A Slowing Economy'
Latest MarketBeat
- Celebrate July 4th with These Red, White, & Blue Chip Stocks
- AbbVie Stock: A Perfect Dip for Investors to Buy
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
- GitLab Stock Rebounds: The Inside Story of Its Comeback
- Is Rivian Stock on the Verge of a 100% Rally?
- Clarivate: The Cheapest AI Stock Worth Buying?
- Survey: America’s Top 100 Hidden Gem Cities for Startups
- The Meaning Behind Short Interest: Beyond the Short Squeeze Hype
- Savvy Investors' Rate Cut Portfolio: Bonds, Small Caps, Energy
- Generac Holdings Stock: Mixed Signals Leave Investors Uncertain